Icon
+91 94997 68112
Login Register

PERMAX (nda019385)- (EQ 0.05MG BASE,EQ 0.25MG BASE,EQ 1MG BASE)

PERGOLIDE MESYLATE VALEANT PHARM INTL
EQ 0.05MG BASE,EQ 0.25MG BASE,EQ 1MG BASE
Yes No
2009-Oct-19 Expired
None None
None No
Permax is indicated as adjunctive treatment to levodopa/carbidopa in the management of the signs and symptoms of Parkinson’s disease.
0 0 0
Total Other Developers None
Drugs with Suitability No
EQ 0.05MG BASE ** ** - - -
EQ 0.25MG BASE ** ** - - -
EQ 1MG BASE ** ** - - -
NDA Sales Available Total Generic Sales Available
No 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report

Download GenUS Detailed Report

To get detailed report Contact Us

GenUs Advanced Search





Expired
to
Expired
to


Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.